JWJordain Walshon

Jordain Walshon

*This is an algorithmically generated author record based on publicly available information.

Jordain Walshon has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Methylation profiling of plasma cell-free DNA in pediatric brain tumor patients

    by Shejuan An, Kathleen McCortney, Jordain Walshon, Kaethe Leonard, Brian Wray, Matthew McCord, Michael DeCuypere, Craig Horbinski


  • Open Access

    STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

    by Hinda Najem, Spencer T. Lea, Shashwat Tripathi, Lisa Hurley, Chao-Hsien Chen, Ivana William, Moloud Sooreshjani, Michelle Bowie, Genevieve Hartley, Corey Dussold, et al.

    STING agonists can reprogram the tumor microenvironment to induce immunological clearance within the central nervous system. Using multiplexed sequential immunofluorescence (SeqIF) and the Ivy Glioblastoma Atlas, STING expression was found in myeloid populations and in the perivascular space. The STING agonist 8803 increased median survival in multiple preclinical models of glioblastoma, including QPP8, an immune checkpoint blockade–resistant model, where 100% of mice were cured. Ex vivo flow cytometry profiling during the therapeutic window demonstrated increases in myeloid tumor trafficking and activation, alongside enhancement of CD8 + T cell and NK effector responses. Treatment with 8803 reprogrammed microglia to express costimulatory CD80/CD86 and iNOS, while decreasing immunosuppressive CD206 and arginase. In humanized mice, where tumor cell STING is epigenetically silenced, 8803 therapeutic activity was maintained, further attesting to myeloid dependency and reprogramming. Although the combination with a STAT3 inhibitor did not further enhance STING agonist activity, the addition of anti–PD-1 antibodies to 8803 treatment enhanced survival in an immune checkpoint blockade–responsive glioma model. In summary, 8803 as a monotherapy demonstrates marked in vivo therapeutic activity, meriting consideration for clinical translation.


  • Open Access

    Age-related loss of Notch3 underlies brain vascular contractility deficiencies, glymphatic dysfunction, and neurodegeneration in mice

    by Milagros C. Romay, Russell H. Knutsen, Feiyang Ma, Ana Mompeón, Gloria E. Hernandez, Jocelynda Salvador, Snezana Mirkov, Ayush Batra, David P. Sullivan, Daniele Procissi, et al.

    Vascular aging affects multiple organ systems, including the brain, where it can lead to vascular dementia. However, a concrete understanding of how aging specifically affects the brain vasculature, along with molecular readouts, remains vastly incomplete. Here, we demonstrate that aging is associated with a marked decline in Notch3 signaling in both murine and human brain vessels. To clarify the consequences of Notch3 loss in the brain vasculature, we used single-cell transcriptomics and found that Notch3 inactivation alters regulation of calcium and contractile function and promotes a notable increase in extracellular matrix. These alterations adversely impact vascular reactivity, manifesting as dilation, tortuosity, microaneurysms, and decreased cerebral blood flow, as observed by MRI. Combined, these vascular impairments hinder glymphatic flow and result in buildup of glycosaminoglycans within the brain parenchyma. Remarkably, this phenomenon mirrors a key pathological feature found in brains of patients with CADASIL, a hereditary vascular dementia associated with NOTCH3 missense mutations. Additionally, single-cell RNA sequencing of the neuronal compartment in aging Notch3-null mice unveiled patterns reminiscent of those observed in neurodegenerative diseases. These findings offer direct evidence that age-related NOTCH3 deficiencies trigger a progressive decline in vascular function, subsequently affecting glymphatic flow and culminating in neurodegeneration.


  • Open Access

    Cancer-associated fibroblast–secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas

    by Shashwat Tripathi, Hinda Najem, Corey Dussold, Sebastian Pacheco, Jason Miska, Kathleen McCortney, Alicia Steffens, Jordain Walshon, Daniel Winkowski, Michael Cloney, et al.

    A recently published JCI paper revealed that cancer-associated fibroblasts (CAFs) are present in glioblastoma and are defined by the presence of 9 transcriptional markers (1). CAFs can form a barrier around cancer cells that prevents their detection by T cells (2). The normal brain has low levels of collagen, but deposition increases in gliomas, especially around vessels. In addition to collagen facilitating tumor invasion and providing a niche for cancer stem cells, collagen has also been shown to trigger immune suppression through LAIR1-mediated T cell exhaustion and alternative activation of macrophages (3, 4). CAFs were identified from single cells isolated from 21 samples (high-grade gliomas [HGGs], 5; pilocytic astrocytomas [PAs], 13; and normal brains [NBs], 3) by examining differential expressed genes against known CAF markers and CAF subtype markers (Figure 1A). The percentage of CAFs was a function of glioma grade, with 1% CAFs present in NBs/low-grade gliomas and nearly 20% in HGGs with an enrichment of the immunomodulatory CAF subtype (Figure 1, B and C). Gene ontology analysis suggested CAF-mediated immune suppression and migration inhibition (Figure 1D). To ascertain the collagen types produced by CAFs, scRNA-Seq data from our pediatric glioma cohort complemented with public adult glioblastoma data sets (5) were analyzed and showed that CAFs expressed COL6A1/A2 > COL4A1, COL9A3, COL12A1 > COL1A (Figure 1E and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/ JCI176613DS1). ELISA confirmed collagen production by human glioblastoma CAFs at 773 μg/mL. Within the public data set (5), the CAF populations are included in the pericyte compartment. Pericytes expressed the greatest diversity of collagen subtypes and were the main source of COL1A1/A2, COL3A1, COL4A1/A2, COL5A1/A2, COL6A1/A2/A3, and COL18A1; endothelial cells were also a source of COL4A1/A2 and COL18A1. Glioma cells expressed modest levels of COL6A1 and COL9A3 (Supplemental Figure 1A). Prognostic analysis of collagen subtypes from The Cancer Genome Atlas revealed that 6 types were negatively associated with outcome, including COL1A2 (high vs. low expression, 12.3 vs. 16.1 months; HR = 0.68; P = 0.03); COL6A1 (11.9 vs. 15.9 months; HR = 0.53; P = <0.01); COL8A2 (12.6 vs. 15 months; HR = 0.65; P = 0.02); COL22A1 (11.8 vs. 15.4 months; HR = 0.67; P = 0.03); COL24A1 (11.8 vs. 15 months; HR = 0.64; P = 0.01); and COL27A1 (11.8 vs. 15.8 months; HR = 0.63; P = 0.01) (Supplemental Figure 1B). Among the most frequently expressed and prognostic collagens, COL1A2, COL4A1, and COL6A1 were enriched near the hyperplastic vessels and microvascular proliferation, whereas COL1A2 and COL4A1 were enriched in the perinecrotic regions (Supplemental Figure 1C). To validate these findings, multiplex imaging demonstrated that CAFs were embedded in COL6A1/A2 within HGGs (Figure 1F and Supplemental Video 1). COL1A and COL4A were expressed in tumor glomeruloid struc


  • Open Access

    Postoperative risk of IDH mutant glioma–associated seizures and their potential management with IDH mutant inhibitors

    by Michael R. Drumm, Wenxia Wang, Thomas K. Sears, Kirsten Bell-Burdett, Rodrigo Javier, Kristen Y. Cotton, Brynna Webb, Kayla Byrne, Dusten Unruh, Vineeth Thirunavu, et al.

    Seizures are a frequent complication of adult-type diffuse gliomas, and are often difficult to control with medications. Gliomas with mutations in isocitrate dehydrogenase 1 or 2 (IDHmut) are more likely than IDH–wild type (IDHwt) gliomas to cause seizures as part of their initial clinical presentation. However, whether IDHmut is also associated with seizures during the remaining disease course, and whether IDHmut inhibitors can reduce seizure risk, are unclear. Clinical multivariable analyses showed that preoperative seizures, glioma location, extent of resection, and glioma molecular subtype (including IDHmut status) all contributed to postoperative seizure risk in adult-type diffuse glioma patients, and that postoperative seizures were often associated with tumor recurrence. Experimentally, the metabolic product of IDHmut, d-2-hydroxyglutarate, rapidly synchronized neuronal spike firing in a seizure-like manner, but only when non-neoplastic glial cells were present. In vitro and in vivo models recapitulated IDHmut glioma–associated seizures, and IDHmut inhibitors currently being evaluated in glioma clinical trials inhibited seizures in those models, independent of their effects on glioma growth. These data show that postoperative seizure risk in adult-type diffuse gliomas varies in large part by molecular subtype, and that IDHmut inhibitors could play a key role in mitigating such risk in IDHmut glioma patients.